Increased Rates of Pneumonitis in Patients Receiving Stereotactic Ablative Radiation Therapy for Central Versus Peripheral Lung Tumors

Abstract

Recently there has been controversy in the literature regarding treatment of central lung tumors with stereotactic ablative radiation therapy (SABR) from a toxicity standpoint, with RTOG 0813 designed to help address this issue. Here we report our institution’s experience in treating central lung tumor patients with SABR, compared to similarly treated peripheral lung tumors.